Kyung NAM Pharm경남제약
053950 · KOSDAQ · ₩053950 · 경남제약
₩1,710▼ ₩64 (3.61%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩56B | ₩61B | ₩59B | ₩59B | ₩65B |
| Cost of sales | ₩41B | ₩43B | ₩40B | ₩41B | ₩44B |
| Gross profit | ₩15B | ₩17B | ₩19B | ₩18B | ₩21B |
| Operating income | −₩1.7B | ₩17M | −₩1.3B | −₩2.3B | −₩7.3B |
| Net income | −₩9B | ₩6.4B | −₩18B | −₩6.5B | −₩3.2B |
| Net income to shareholders | −₩9B | ₩6.4B | −₩18B | −₩6.5B | −₩3.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩156B | ₩166B | ₩141B | ₩145B | ₩125B |
| Current assets | ₩79B | ₩78B | ₩53B | ₩75B | ₩54B |
| Cash and equivalents | ₩6.3B | ₩51B | ₩15B | ₩41B | ₩22B |
| Total liabilities | ₩47B | ₩51B | ₩57B | ₩44B | ₩52B |
| Current liabilities | ₩46B | ₩46B | ₩52B | ₩44B | ₩25B |
| Borrowings | ₩35B | ₩37B | ₩40B | ₩32B | ₩39B |
| Total equity | ₩108B | ₩115B | ₩84B | ₩100B | ₩73B |
| Shareholders' equity | ₩108B | ₩115B | ₩84B | ₩100B | ₩73B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.7B | ₩1.1B | ₩2.3B | ₩1.9B | −₩9B |
| Capital spending | ₩1.3B | ₩1.1B | ₩391M | ₩2.9B | ₩2.3B |
| Free cash flow | −₩2.9B | ₩8.2M | ₩2B | −₩982M | −₩11B |
Consolidated where available. Amounts in won.
Also known as: Kyung NAM Pharm / 경남제약 / 053950 / KRX:053950
Source: KRX statistical information